Author

Jean Lang

sanofi pasteur - Cited by 7,759 - dengue rabies

Biography

Jean Lang joined Sanofi Pasteur R&D in 1991 and Pharma in1989, was on the Lyon faculty of Medicine (Clinical Pharmacology Assistant 1983-1988) and Lyon 1 University of Biological Sciences (Experimental Pharmacology Assistant 1982-1988), M.D. (1983), Clinical Pharmacokinetics MSc (1984) and PhD (1987) with his thesis on Experimental Pharmacology. At J&J from 1989 -1991,he worked on rHuEPO, Mabs and various Biotech RD projects.
Title
Cited by
Year
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
A Sabchareon, D Wallace, C Sirivichayakul, K Limkittikul, ...The Lancet 380 (9853), 1559-1567, 2012201
926
2012
From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine
B Guy, B Barrere, C Malinowski, M Saville, R Teyssou, J LangVaccine 29 (42), 7229-7241, 2011201
394
2011
Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward
B Guy, O Briand, J Lang, M Saville, N JacksonVaccine 33 (50), 7100-7111, 2015201
179
2015
Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines
RZ Capeding, IA Luna, E Bomasang, S Lupisan, J Lang, R Forrat, ...Vaccine 29 (22), 3863-3872, 2011201
156
2011
Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity
J Poo, F Galan, R Forrat, B Zambrano, J Lang, GH DayanThe Pediatric infectious disease journal 30 (1), e9-e17, 2011201
133
2011
Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans
M Qiao, D Shaw, R Forrat, A Wartel-Tram, J LangThe American journal of tropical medicine and hygiene 85 (4), 724, 2011201
70
2011
Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and children
NH Tran, CQ Luong, TQH Vu, R Forrat, J Lang, QD Vu, A Bouckenooghe, ...J Vaccines Vaccin 3 (7), 1-8, 2012201
56
2012
Vaccination against dengue: challenges and current developments
B Guy, J Lang, M Saville, N JacksonAnnual review of medicine 67, 387-404, 2016201
55
2016
Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus
GH Dayan, K Pugachev, J Bevilacqua, J Lang, TP MonathViruses 5 (12), 3048-3070, 2013201
51
2013
Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore
A Harenberg, S Begue, A Mamessier, S Gimenez-Fourage, C Ching Seah, ...Human vaccines & immunotherapeutics 9 (11), 2317-2325, 2013201
51
2013
Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses
V Barban, JL Munoz-Jordan, GA Santiago, N Mantel, Y Girerd, S Gulia, ...Virology 429 (2), 91-98, 2012201
49
2012
Dengue vaccine prospects: a step forward
B Guy, J Almond, J LangThe Lancet 377 (9763), 381-382, 2011201
46
2011
Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated …
C Balas, A Kennel, F Deauvieau, R Sodoyer, N Arnaud-Barbe, J Lang, ...Journal of Infectious Diseases 203 (1), 103-108, 2011201
40
2011
Decay and persistence of maternal dengue antibodies among infants in Bangkok
WG Van Panhuis, C Luxemburger, K Pengsaa, K Limkittikul, ...The American journal of tropical medicine and hygiene 85 (2), 355, 2011201
37
2011
Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naive adults in Mexico
GH Dayan, JF Galán-Herrera, R Forrat, B Zambrano, A Bouckenooghe, ...Human vaccines & immunotherapeutics 10 (10), 2853-2863, 2014201
31
2014
Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses
N Mantel, Y Girerd, C Geny, I Bernard, J Pontvianne, J Lang, V BarbanVaccine 29 (38), 6629-6635, 2011201
31
2011
Preparing for introduction of a dengue vaccine: recommendations from the 1st Dengue v2V Asia-Pacific Meeting
SK Lam, D Burke, MR Capeding, CK Chong, L Coudeville, J Farrar, ...Vaccine 29 (51), 9417-9422, 2011201
31
2011
Development of Sanofi Pasteur tetravalent dengue vaccine
J LangRevista do Instituto de Medicina Tropical de São Paulo 54, 15-17, 2012201
26
2012
Stability of yellow fever virus under recombinatory pressure as compared with chikungunya virus
CE McGee, KA Tsetsarkin, B Guy, J Lang, K Plante, DL Vanlandingham, ...PLoS One 6 (8), e23247, 2011201
25
2011
Improvement of the dengue virus (DENV) nonhuman primate model via a reverse translational approach based on dengue vaccine clinical efficacy data against DENV-2 and-4
V Barban, N Mantel, A De Montfort, A Pagnon, F Pradezynski, J Lang, ...Journal of virology 92 (12), 10.1128/jvi. 00440-18, 2018201
15
2018

Referred From: https://scholar.google.com/citations?hl=en&user=2AY8KpMAAAAJ

Cited by
Citations 7759
h-index 47
i10-index 100
Recommended Journals
Open Access Journals